Table 3.
Correlation between KRAS/ NRAS mutations and clinicopathological features.
| Clinicopathological features | Number | KRAS status | NRAS status | ||||
|---|---|---|---|---|---|---|---|
| Wild typeN = 56 (%) | Mutant typeN = 40 (%) | P-value | Wild typeN = 89 (%) | Mutant typeN = 7 (%) | P-value | ||
| Age (years) | |||||||
| ≥60 (n = 65) | 65 | 33 (58.9) | 32 (80) | 0.029 | 62 (69.7) | 3 (42.9) | 0.149 |
| <60 (n = 31) | 31 | 23 (41.1) | 8 (20) | 27 (30.3) | 4 (57.1) | ||
| Sex | |||||||
| Male (n = 60) | 60 | 36 (64.3) | 24 (60) | 0.669 | 54 (60.7) | 6 (85.7) | 0.184 |
| Female (n = 36) | 36 | 20 (35.7) | 16 (40) | 35 (39.3) | 1 (14.3) | ||
| Tumor location | |||||||
| Right colon (n = 25) | 25 | 19 (33.9) | 6 (15) | 0.037 | 22 (24.7) | 3 (42.9) | 0.260 |
| Left colon (n = 71) | 71 | 37 (66.1) | 34 (85) | 67 (75.3) | 4 (57.1) | ||
| Histological type | |||||||
| NMC (n = 67) | 67 | 35 (62.5) | 32 (80) | 0.066 | 64 (71.9) | 3 (42.9) | 0.120 |
| MC (n = 29) | 29 | 21 (37.5) | 8 (20) | 25 (28.1) | 4 (57.1) | ||
| Differentiation | |||||||
| Well (n = 47) | 47 | 22 (39.3) | 25 (62.5) | 45 (50.6) | 2 (28.6) | 0.151 | |
| Moderate (n = 46) | 46 | 31 (55.4) | 15 (37.5) | 0.044 | 42 (47.2) | 4 (57.1) | |
| Poor (n = 3) | 3 | 3 (5.3) | 0 (0) | 2 (2.2) | 1 (14.3) | ||
| Stages | |||||||
| I, II (n = 32) | 32 | 19 (33.9) | 13 (32.5) | 0.884 | 27 (30.3) | 5 (71.4) | 0.039 |
| II, IV (n = 64) | 64 | 37 (66.1) | 27 (67.5) | 62 (69.7) | 2 (28.6) | ||
| Lymph node metastasis | |||||||
| No (n = 33) | 33 | 21 (37.5) | 12 (30) | 0.446 | 28 (31.5) | 5 (71.4) | 0.045 |
| Yes (n = 63) | 63 | 35 (62.5) | 28 (70) | 61(68.5) | 2 (28.6) | ||